Novartis, Vymada and India’s Patent Regime: A Turning Point
Recently the Indian Patent Office revoked the patent granted to Novartis for a heart failure drug named Vymada also known as Entresto, which was a combination of drug sacubitril and valsartan. The main grounds of revocation of patent was lack of novelty and inventive step and also it was invariably coming under section 3(d) of […]